文献速递治疗药物监测与药物基因组学特殊人群用药

高龄与HIV感染者血浆及脑脊液中多替拉韦暴露升高相关

Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV.
PubMed 文献 · Clin Pharmacokinet · 2021-01-01

该回顾性治疗药物监测分析纳入207例每日一次多替拉韦且无相互作用的HIV感染者(457份血清)及41例脑脊液样本,发现年龄>50岁者脑脊液多替拉韦浓度及脑脊液/血浆比值显著更高,血清谷浓度随年龄增长呈线性回归显著关联。

要点

  • 年龄>50岁者脑脊液多替拉韦浓度(13.8 vs 7.3 ng/mL)及脑脊液/血浆比值(0.57% vs 0.32%)显著更高。
  • 线性回归显示年龄对多替拉韦血清谷浓度有显著影响(p=0.0013)。
  • 脑脊液多替拉韦浓度与血浆浓度(ρ=0.374)及年龄(ρ=0.537)相关。

核心结论

  • 高龄HIV感染者多替拉韦在血清和脑脊液中的暴露均升高。

研究设计与样本

  • 回顾性治疗药物监测登记分析,纳入207例每日一次多替拉韦且无合并相互作用药物及显著临床状况的HIV感染者(457份血清样本)和41例接受多替拉韦的脑脊液样本患者。

主要发现

  • 年龄>50岁者多替拉韦血清峰浓度[4230 ng/mL(2919-5272)vs 3830 ng/mL(2311-5057),p=0.311]及谷浓度[966 ng/mL(460-2085)vs 838 ng/mL(362-1587),p=0.056]呈非显著或边缘性升高。
  • 脑脊液多替拉韦浓度与血浆浓度相关(ρ=0.374,p=0.016),与年龄相关(ρ=0.537,p=0.003)。
  • 年龄>50岁者脑脊液多替拉韦浓度(13.8 vs 7.3 ng/mL,p=0.015)及脑脊液/血浆比值(0.57% vs 0.32%,p=0.017)更高。

临床怎么用

  • 对高龄HIV感染者使用多替拉韦时,可关注血清及脑脊液暴露升高,必要时结合治疗药物监测评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with human immunodeficiency virus are ageing under combination antiretroviral treatments but data on drug exposure in serum and cerebrospinal fluid are limited. Dolutegravir is a widely used second-generation integrase strand transfer inhibitor: conflicting data suggest that neuropsychiatric side effects may present at a higher frequency in patients with higher dolutegravir serum concentrations. METHODS: We performed a retrospective analysis of our therapeutic drug monitoring registry identifying patients receiving once-daily dolutegravir without concomitant interacting drugs and significant clinical conditions. Data were analysed stratifying time after drug dose intake (maximum concentration 0.5-4 and trough concentration 21-27 h). Cerebrospinal fluid samples from patients enrolled in neurological studies and receiving dolutegravir were analysed for dolutegravir cerebrospinal fluid concentrations and cerebrospinal fluid-to-plasma ratios. Serum and cerebrospinal fluid concentrations were measured through validated chromatographic methods. RESULTS: We included 207 (providing 457 serum samples) and 41 patients (providing 41 cerebrospinal fluid samples). Participants were mostly male (68.2-72.8%) of median age of 50 years (50-53 years). Non-significant changes in dolutegravir maximum concentration and trough concentration were observed with age at Spearman's test (p values > 0.05); linear logistic regression showed a significant effect of age on dolutegravir trough concentration (p = 0.0013) (Fig. 1). Dolutegravir maximum concentration [3830 ng/mL (2311-5057) vs 4230 ng/mL (2919-5272), p = 0.311] and trough concentration [838 ng/mL (362-1587) vs 966 ng/mL (460-2085), p = 0.056] were non-significantly or borderline higher in patients aged > 50 years. Cerebrospinal dolutegravir concentrations were associated with plasma concentrations (ρ = 0.374, p = 0.016) and age (ρ = 0.537, p = 0.003); cerebrospinal fluid dolutegravir concentrations (13.8 vs 7.3 ng/mL, p = 0.015) and cerebrospinal fluid-to-plasma ratios (0.57 vs 0.32%, p = 0.017] were higher in participants aged > 50 years. CONCLUSIONS: We observed an increase in dolutegravir exposure in serum and in cerebrospinal fluid in older patients living with human immunodeficiency virus.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Calcagno A, Moltó J, Borghetti A, et al. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. Clin Pharmacokinet. 2021. PMID: 32737820. doi:10.1007/s40262-020-00916-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。